Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




CHI3L1 Protein Differentially Expressed in Appendicitis and Appendix Carcinomas

By LabMedica International staff writers
Posted on 06 Dec 2022
Print article
Image: Olympus Fluoview FV3000 with MPM System, a multispectral, multiphoton laser scanning microscope (Photo courtesy of University Of California, Irvine)
Image: Olympus Fluoview FV3000 with MPM System, a multispectral, multiphoton laser scanning microscope (Photo courtesy of University Of California, Irvine)

Appendicitis is inflammation of the appendix. Symptoms commonly include right lower abdominal pain, nausea, vomiting, and decreased appetite. However, approximately 40% of people do not have these typical symptoms. Adenocarcinoma of the appendix is an epithelial cancer of the appendix.

Chitinase-3-like protein 1 (CHI3L1) is a 40-kDa heparin-and-chitin binding glycoprotein, mainly produced by some cell types, including colonic epithelial cells (CECs) chondrocytes, osteosarcoma cells, macrophages, smooth muscle cells, and neutrophils. High levels of CHI3L1 are associated with poor prognosis and accelerate the proliferation of colon cancer cells.

Clinical Laboratorians at The Affiliated Taian City Central Hospital of Qingdao University (Taian, China) collected blood and appendix samples from 46 acute appendicitis and 14 appendix carcinomas that had surgery at the hospital between May 2019 and November 2021. The patients were divided the acute appendicitis group into acute uncomplicated appendicitis (AUA), suppurative appendicitis (SA), and gangrenous appendicitis (GA). The appendix carcinoma group was divided into appendiceal neuroendocrine neoplasms (ANENs) and appendiceal mucinous neoplasms (AMN). Controls were 32 healthy donors.

The patients' venous blood samples were taken before the appendectomy. Blood neutrophil to lymphocyte ratio (NLR), CHI3L1, C-reactive protein (CRP), interleukin-6 (IL-6, Shenzhen Lifotronic Biotech Co. Ltd, Shenzhen, China), and serum amyloid A (SAA, Upper Bio-TECH Pharma Co. Ltd, Shanghai, China) were measured. NLR was analyzed from a blood routine test. For immunohistochemical staining, sections were rinsed in distilled water three times, and the Quick Antigen Retrieval Solution (Beyotime Biotechnology, Haimen, China) was used for antigen retrieval. Next, 3% bovine serum albumin was used for nonspecific binding blockage, and the sections were incubated with an anti-CHI3L1 antibody at 4° C overnight. Fluorescence images were obtained using an Olympus FV3000 confocal microscope (Olympus, Center Valley, Pa, USA).

The investigators reported that compared with the controls, CHI3L1 serum levels were up-regulated in SA, GA, and AMN groups, while no significant difference was observed in the AUA and ANEN groups. Immunofluorescence revealed that CHI3L1 expression was high in macrophages and adenocarcinoma cells of appendix tissues, but not in the neuroendocrine carcinoma tissues. Moreover, levels of NLR and CRP in the SA and GA groups were considerably higher than in the control group. IL-6 and SAA in SA, GA, ANENs, and AMN groups were also increased compared with the control group. In addition, CHI3L1 displayed good performance in predicting appendicitis, with an AUC of 0.862.

The authors concluded that the patients with appendicitis had an enhanced CHI3L1 expression, associated with increased NLR, CRP, IL-6, and SAA. Moreover, CHI3L1 was crucial in patients with appendiceal neuroendocrine neoplasms. The study was published on November 29, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
The Affiliated Taian City Central Hospital of Qingdao University
Shenzhen Lifotronic Biotech Co. Ltd
Upper Bio-TECH Pharma Co. Ltd
Beyotime Biotechnology
Olympus

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.